Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Femara maintenance in ER-positive ovarian cancer
NCT04111978Phase 3Recruiting
- Sponsor
- Swiss GO Trial Group
- Start
- Nov 2020
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of letrozole in Epithelial Ovarian Cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Swiss GO Trial Group. Started Nov 2020; status: recruiting.
02
Drugs
letrozole
03
Conditions
Epithelial Ovarian Cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04111978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111978.